Trial · NCT06856031
the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis
NCT06856031, Completed, Second Affiliated Hospital of Wenzhou Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis. Trials, record NCT06856031. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06856031
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis
- NCT number
- NCT06856031
- Status
- Completed
- Enrollment
- 152 participants, actual
- Lead sponsor
- Second Affiliated Hospital of Wenzhou Medical University
- Conditions
- IBD (Inflammatory Bowel Disease)
- Interventions
- Optimized Treatment (OPT)
- First posted
- 2025-03-04
- Last updated
- 2025-03-04
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Drug retention rates analyzed at weeks 54 of vedolizumab treatment | at week 54 | the drug retention rate of vedolizumab |
| Primary | Drug retention rates analyzed at weeks 108 of vedolizumab treatment | at week 108 | the drug retention rate of vedolizumab |
| Secondary | Analyze the impact of baseline MES on VDZ drug retention rates | at week 54 and 108 | Analyze the difference in baseline MES between VDZ-continued group and VDZ-discontinued group (Baseline is defined as week 0 of VDZ treatment). The Mayo endoscopic score (MES) was used to assess the degree of intestinal inflammation, with a score of MES=0 defined as mucosal healing, MES=1 as mild, MES=2 as moderate, and MES=3 as severe. |
| Secondary | Analyze the impact of baseline disease sites on VDZ drug retention rates | at week 54 and 108 | Analyze the difference in disease sites between VDZ-continued group and VDZ-discontinued group (Baseline is defined as week 0 of VDZ treatment). Disease sites were categorized into proctitis (E1), left hemicolonitis (E2) and extensive colitis (E3) based on the Montreal UC phenotypic classification criteria. |
| Secondary | Analyze the impact of baseline modified Mayo score on VDZ drug retention rates | at week 54 and 108 | Analyze the difference in the baseline modified Mayo score between VDZ-continued group and VDZ-discontinued group (Baseline is defined as week 0 of VDZ treatment). The modified Mayo score was employed to assess UC disease activity. A modified Mayo score of ≤5 was defined as mild activity, 6-10 as moderate activity, and ≥11 as severe activity. |
| Secondary | Analyze the impact of duration of disease on VDZ drug retention rates | at week 54 and 108 | Analyze the difference in duration of disease (in years) between VDZ-continued group and VDZ-discontinued group. |
| Secondary | Analyze the impact of baseline C-reactive protein in peripheral blood on VDZ drug retention rates | at week 54 and 108 | Analyze the difference in baseline C-reactive protein (mg/L) in peripheral blood between VDZ-continued group and VDZ-discontinued group (Baseline is defined as week 0 of VDZ treatment). |
| Secondary | Analyze the impact of baseline erythrocyte sedimentation rate on VDZ drug retention rates | at week 54 and 108 | Analyze the difference in baseline erythrocyte sedimentation rate (mm/h) between VDZ-continued group and VDZ-discontinued group (Baseline is defined as week 0 of VDZ treatment). |
| Secondary | Analyze the impact of baseline 25(OH) D in peripheral blood on VDZ drug retention rates | at week 54 and 108 | Analyze the difference in baseline 25(OH) D in peripheral blood (ng/mL) between VDZ-continued group and VDZ-discontinued group (Baseline is defined as week 0 of VDZ treatment). |
| Secondary | Analyze the impact of baseline serum albumin in peripheral blood on VDZ drug retention rates | at week 54 and 108 | Analyze the difference in baseline serum albumin (g/L) in peripheral blood between VDZ-continued group and VDZ-discontinued group (Baseline is defined as week 0 of VDZ treatment). |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06856031
GET https://conductscience.org/api/trials/v1/NCT06856031/registered